On April 1, 2026, Caris Life Sciences, Inc. entered a Financing Agreement granting them $400 million in new loans, plus up to $300 million for future acquisitions and $500 million more if needed. This reshapes their financial obligations, replacing a previous credit deal and ensuring funds for growth.